Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: Effect on time to readmission

International Clinical Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 159-164

  Valevski, Avi ^a   Gilat, Yaron ^a   Olfson, Mark ^c   Benaroya Milshtein, Noa ^a   Weizman, Abraham ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

clozapine; first generation antipsychotics; readmission,schizophrenia; second generation antipsychotics

Indexed keywords

CLOTIAPINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL DECANOATE;

ADJUVANT THERAPY; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK REDUCTION; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISRAEL; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859234655     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328350ddbe     Document Type: Article

References (35)

1. Castro AP, Elkis H (2007). Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr 29:207-212.
2. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700-706. (Pubitemid 38445515)
3. Conley RR, Kelly DL, Love RC, McMahon RP (2003). Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15:23-31. (Pubitemid 36723638)
4. Correll CU, Frederickson AM, Kane JM, Manu P (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89:91-100. (Pubitemid 44881290)
5. Davis JM, Chen N (2003). Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64 (Suppl 16):24-33. (Pubitemid 37523325)
6. Essali A, Al-Haj HN, Li C, Rathbone J (2009). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 21:CD000059.
7. Fleischhacker WW, Hummer M (1997). Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 53:915-929. (Pubitemid 27254570)
8. Gaebel W, Pietzcker A, Poppenberg A (1981). Predictors of the course of schizophrenic diseases under neuroleptic long-term medication (author's transl). Pharmacopsychiatria 14:180-188. (Pubitemid 12236924)
9. Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ 321:1371-1376.
10. Gianfrancesco F,Wang RH, Pesa J, Rajagopalan K (2006). Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. Int J Clin Pract 60:1419-1424. (Pubitemid 44560341)
11. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520-532.
12. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. (2006). Randomized controlled trial of the effect on quality of life of second-vs. firstgeneration antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in Schizophrenia Study (CUtLASS 1271). Arch Gen Psychiatry 63:1079-1087. (Pubitemid 44498387)
13. Kane JM, Correll CU (2010). Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71:1115-1124.
14. Kane JM, Leucht S, Carpenter D, Docherty JP (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 (Suppl 12):5-19.
15. Kennedy J, Tien YY, Cohen LJ, Sclar DA, Liu D, Blodgett EG, et al. (2009). The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 medicare current beneficiary survey. Clin Ther 31:2931-2939.
16. Leucht S, Kissling W, McGrath J (2004). Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 65:177-186.
17. Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, et al. (2006). Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 10:iii-xi.
18. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. (Pubitemid 41345943)
19. Lukoff D, Liberman RP, Nuechterlein KH (1986). Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr Bull 12:578-602.
20. Mojtabai R, Olfson M (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67: 26-36.
21. Olfson M, Mechanic D, Boyer CA, Hansell S, Walkup J, Weiden PJ (1999). Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 187:721-729. (Pubitemid 30036718)
22. Olfson M, Marcus SC, Ascher-Svanum H (2007). Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 33:1379-1387. (Pubitemid 350022772)
23. Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML (2002). One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 53:891-893. (Pubitemid 34742776)
24. Patel NC, Crismon ML, Miller AL, Johnsrud MT (2005). Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 25:1242-1247. (Pubitemid 41242581)
25. Pollack S, Woerner MG, Howard A, Fireworker RB, Kane JM (1998). Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull 34:89-92. (Pubitemid 28176307)
26. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M (2001). Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 158:266-269. (Pubitemid 32116523)
27. Russo J, Roy-Byrne P, Jaffe C, Ries R, Dagadakis C, Avery D (1997). Psychiatric status, quality of life, and level of care as predictors of outcomes of acute inpatient treatment. Psychiatr Serv 48:1427-1434. (Pubitemid 27465170)
28. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
29. Schooler NR (2003). Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 64 (Suppl 16):14-17. (Pubitemid 37523323)
30. Swett C (1995). Symptom severity and number of previous psychiatric admissions as predictors of readmission. Psychiatr Serv 46:482-485.
31. Tandon R, Fleischhacker WW (2005). Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79:145-155. (Pubitemid 41457255)
32. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603-609.
33. Valevski A, Olfson M, Weizman A, Shiloh R (2007). Risk of readmission in compulsorily and voluntarily admitted patients. Soc Psychiatry Psychiatr Epidemiol 42:916-922.
34. Wahlbeck K, Cheine M, Essali A, Adams C (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156:990-999. (Pubitemid 29302789)
35. Zink M, Englisch S, Meyer-Lindenberg A (2010). Polypharmacy in schizophrenia. Curr Opin Psychiatry 23:103-111.